May 11, 2020
Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 05, 2020
Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by Alexion
May 05, 2020
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Portola Pharmaceuticals, Inc.
May 01, 2020
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 23, 2020
Portola Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 11, 2020
Apr 01, 2020
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 24, 2020
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Feb 12, 2020
Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020
Feb 03, 2020
Portola Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President and Chief Medical Officer
Jan 27, 2020
PTLA LOSSES ALERT: Bernstein Liebhard LLP Reminds Investors of its Investigation into Portola Pharmaceuticals, Inc., and Encourages Investors with Losses to Contact the Firm
Dec 23, 2019
Portola Pharmaceuticals to Webcast Corporate Update on January 14, 2020
Dec 17, 2019
Portola Pharmaceuticals to Support New American Heart Association Initiative to Address Hemorrhagic Stroke
Nov 01, 2019
Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 19, 2019
Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors
Aug 22, 2019
Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Aug 12, 2019
Portola Pharmaceuticals Announces Proposed Offering of Common Stock
Jul 17, 2019
Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019
Apr 23, 2019
Historic Portola Gardens Undergoes Major Renovations, Unique Setting Offers Seniors A True Sense of Home in Award-Nominated Community